Market closed
AC Immune/$ACIU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AC Immune
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Ticker
$ACIU
Sector
Trading on
Industry
Biotechnology
Headquarters
Lausanne, Switzerland
Employees
153
ISIN
CH0329023102
Website
AC Immune Metrics
BasicAdvanced
$164M
-
-$0.63
1.62
-
Price and volume
Market cap
$164M
Beta
1.62
52-week high
$4.98
52-week low
$1.43
Average daily volume
164K
Financial strength
Current ratio
1.533
Quick ratio
1.497
Long term debt to equity
4.369
Total debt to equity
5.459
Interest coverage (TTM)
-342.25%
Management effectiveness
Return on assets (TTM)
-17.07%
Return on equity (TTM)
-43.50%
Valuation
Price to revenue (TTM)
4.874
Price to book
1.75
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
3.044
Growth
Revenue change (TTM)
91.20%
Earnings per share change (TTM)
-15.41%
3-year earnings per share growth (CAGR)
-18.61%
What the Analysts think about AC Immune
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AC Immune stock.
AC Immune Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AC Immune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AC Immune News
AllArticlesVideos
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewsWire·1 week ago
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
GlobeNewsWire·1 month ago
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AC Immune stock?
AC Immune (ACIU) has a market cap of $164M as of May 10, 2025.
What is the P/E ratio for AC Immune stock?
The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of May 10, 2025.
Does AC Immune stock pay dividends?
No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next AC Immune dividend payment date?
AC Immune (ACIU) stock does not pay dividends to its shareholders.
What is the beta indicator for AC Immune?
AC Immune (ACIU) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.